Business Description
Catalyst Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
Description
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 54.5 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 32.53 | |||||
| Beneish M-Score | -2.85 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 539.2 | |||||
| 3-Year Book Growth Rate | 59.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 21.03 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.59 | |||||
| 9-Day RSI | 43.39 | |||||
| 14-Day RSI | 45.95 | |||||
| 6-1 Month Momentum % | 74.11 | |||||
| 12-1 Month Momentum % | 181.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.79 | |||||
| Quick Ratio | 10.44 | |||||
| Cash Ratio | 9.82 | |||||
| Days Inventory | 104.78 | |||||
| Days Sales Outstanding | 16.99 | |||||
| Days Payable | 44.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.1 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.64 | |||||
| Operating Margin % | 42.64 | |||||
| Net Margin % | 31.97 | |||||
| ROE % | 25.81 | |||||
| ROA % | 23.01 | |||||
| ROIC % | 167.53 | |||||
| ROC (Joel Greenblatt) % | 1611.7 | |||||
| ROCE % | 33.8 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 24.55 | |||||
| Forward PE Ratio | 15.78 | |||||
| PE Ratio without NRI | 24.55 | |||||
| Price-to-Owner-Earnings | 20.42 | |||||
| PS Ratio | 8.01 | |||||
| PB Ratio | 5.33 | |||||
| Price-to-Tangible-Book | 5.4 | |||||
| Price-to-Free-Cash-Flow | 18.01 | |||||
| Price-to-Operating-Cash-Flow | 18.01 | |||||
| EV-to-EBIT | 14.7 | |||||
| EV-to-Forward-EBIT | 9.43 | |||||
| EV-to-EBITDA | 14.68 | |||||
| EV-to-Revenue | 6.28 | |||||
| EV-to-Forward-Revenue | 4.61 | |||||
| EV-to-FCF | 14.5 | |||||
| Price-to-Projected-FCF | 3.67 | |||||
| Price-to-Graham-Number | 2.45 | |||||
| Price-to-Net-Current-Asset-Value | 6.02 | |||||
| Price-to-Net-Cash | 6.72 | |||||
| Earnings Yield (Greenblatt) % | 6.78 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CPRX
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 170.465 | ||
| EPS (TTM) ($) | 0.51 | ||
| Beta | 0.66 | ||
| Volatility % | 68.02 | ||
| 14-Day RSI | 45.95 | ||
| 14-Day ATR ($) | 0.749055 | ||
| 20-Day SMA ($) | 13.582 | ||
| 12-1 Month Momentum % | 181.27 | ||
| 52-Week Range ($) | 5.04 - 17.22 | ||
| Shares Outstanding (Mil) | 102.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Catalyst Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Catalyst Pharmaceuticals Inc Analysis
Share your researchHeadlines
See More
No news.